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TNF-α is the dominant cytokine in inflammatory osteolysis. Using mice whose BM stromal cells and osteoclast precursors are chimeric for the presence of TNF receptors, we found that both cell types mediated the
cytokine’s osteoclastogenic properties. The greater contribution was made, however, by stromal cells that
express the osteoclastogenic cytokine M-CSF. TNF-α stimulated M-CSF gene expression, in vivo, only in the
presence of TNF-responsive stromal cells. M-CSF, in turn, induced the key osteoclastogenic cytokine receptor, receptor activator of NF-κB (RANK), in osteoclast precursors. In keeping with the proproliferative and
survival properties of M-CSF, TNF-α enhanced osteoclast precursor number only in the presence of stromal
cells bearing TNF receptors. To determine the clinical relevance of these observations, we induced inflammatory arthritis in wild-type mice and treated them with a mAb directed against the M-CSF receptor, c-Fms.
Anti–c-Fms mAb selectively and completely arrested the profound pathological osteoclastogenesis attending
this condition, the significance of which is reflected by similar blunting of the in vivo bone resorption marker
tartrate-resistant acid phosphatase 5b (TRACP 5b). Confirming that inhibition of the M-CSF signaling pathway targets TNF-α, anti–c-Fms also completely arrested osteolysis in TNF-injected mice with nominal effect
on macrophage number. M-CSF and its receptor, c-Fms, therefore present as candidate therapeutic targets in
states of inflammatory bone erosion.
*OUSPEVDUJPO
Inflammatory osteolysis attends disorders such as rheumatoid
and psoriatic arthritis, which are among the most crippling of
skeletal diseases. In this circumstance, osteoclasts erode periarticular bone, leading to joint collapse and disfigurement. The
fact that large numbers of such osteoclasts appear juxtaposed
to foci of synovitis suggests that the products of inflammation
mediate cell recruitment.
Osteoclasts have the unique capacity to resorb bone and are derived
from monocyte/macrophage precursors (1). The discovery that
receptor activator of NF-κB ligand (RANKL) is the specific osteoclastogenic cytokine (2, 3) led to the development of techniques whereby
pure populations of osteoclasts can be generated in culture and eventuated in targeted, antiresorptive therapeutic strategies (4).
Other cytokines, however, also have a significant impact on the
osteoclastogenic process, not least of which is TNF-α. This molecule, which is produced in abundance in bone erosive diseases
such as rheumatoid arthritis and periodontitis (5–9), profoundly
accelerates the osteoclastogenic process (10). Interestingly, TNF-α
alone is not sufficient to promote osteoclast precursor differentiation but has an impact only on cells simultaneously stimulated, or
primed, with RANKL (10). Thus, inflammatory osteolysis does not
occur in RANK-deficient mice (11, 12).
The discovery that TNF-α is central to the bone loss attending inflammation led to the development of agents that specifiNonstandard abbreviations used: BMM, bone marrow macrophage; IL-1Ra, IL-1
receptor antagonist; MTT, 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazoliun
bromide; RANK, receptor activator of NF-κB; RANKL, RANK ligand; TNFR, TNF
receptor; TRACP 5b, tartrate-resistant acid phosphatase 5b; TRAP, tartrate-resistant
acid phosphatase.
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cally block the cytokine and thus arrest the resorptive process
(13). Anti-TNF therapy is not without complication, however, as
patients are prone to infections, likely reflecting immune suppression. In addition, it appears that targeting of inflammatory
cytokines such as TNF-α and IL-1 in combination is substantially
more effective than suppression of only 1 (14). Thus, detailing
the panoply of cytokines that mediate inflammatory osteolysis
carries therapeutic implications.
Osteoclastogenesis requires participation of both osteoclast
precursors, principally in the form of BM macrophages (BMMs),
and BM stromal cells and their derivative osteoblasts. In general,
pro-osteoclastogenic agents target BM stromal cells, which are
the source of RANKL. RANKL, in turn, activates its receptor on
BMMs, prompting them to assume the osteoclast phenotype.
TNF-α exerts its osteoclastogenic effect by stimulating stromal
cells to produce RANKL but, at high doses, also directly activates
the osteoclast precursor (15).
Given that both osteoclast precursors and stromal cells are
TNF-α targets, we determined their relative contributions to
inflammatory osteoclastogenesis. We found that while the presence of the cytokine receptor on either cell type was sufficient
to promote some degree of TNF-α–induced osteoclastogenesis,
stromal cells made the greater contribution. Furthermore, TNF-α
induces in vivo expression of the stromal cell product M-CSF,
which maintains survival and longevity of osteoclast precursors and organizes the cytoskeleton of the mature resorptive cell
(16). The fact that M-CSF plays a central role in TNF-induced
osteoclastogenesis is confirmed by the capacity of an antibody
directed against the M-CSF receptor, c-Fms, to completely arrest
pathological osteoclastogenesis and bone resorption, whether
attending inflammatory arthritis or direct injection of TNF-α.
M-CSF and its receptor, c-Fms, are therefore candidate therapeutic targets for inflammatory osteolysis.
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3FTVMUT
BM stromal cells and osteoclast precursors contribute to TNF-induced osteoclastogenesis in vivo. We have shown that both BM stromal cells and
osteoclast precursors are direct targets of TNF-α in the osteoclastogenic process (10, 15). The goal of our first exercise was, therefore, to determine the relative contributions of each. To this end,
we turned to chimeric mice in which either WT or p55/p75 TNF
receptor–deficient (TNFR–/–) BM was transplanted into irradiated
recipients bearing the same or reciprocal genotype. T cells were
eliminated in vivo during the course of the experiment by injection of anti-CD4 and anti-CD8 mAbs (15). Thus, WT BM transplanted into irradiated TNFR–/– (WT to KO) mice serves as a model
in which osteoclast precursors but not BM stromal cells express
TNFRs whereas the opposite obtains in KO to WT chimeras. WT
to WT and KO to KO irradiated and transplanted animals were
used as positive and negative controls, respectively.
Validating the chimeric transplantation model, BMMs isolated
from WT to KO mice expressed both TNFRs in quantities similar
to their WT to WT counterparts (Supplemental Figure 1; available online with this article; doi:10.1172/JCI26132DS1). Similarly, macrophages derived from KO to WT mice were identical
in this regard to those of animals lacking receptors on both cell
types (KO to KO).
Each group of chimeric mice was subjected to daily supracalvarial administration of increasing doses of TNF-α. The animals
were sacrificed on day 5, histological sections of the calvaria were
stained for tartrate-resistant acid phosphatase (TRAP) activity,
and osteoclast number was determined (Figure 1). As expected, KO
to KO animals failed to respond to the cytokine while WT to WT
animals generated osteoclasts in a dose-dependent manner. A similarly progressive albeit more modest increase in osteoclast numThe Journal of Clinical Investigation

ber occurred in mice in which TNFRs were absent in osteoclast
precursors (KO to WT). The response to the cytokine was, however, substantially more blunted in chimeras lacking stromal cell
TNFRs. Thus, while the presence of TNFRs on either stromal cells
or osteoclast precursors was sufficient to promote some degree
of osteoclastogenesis, optimal osteoclast recruitment required
expression of the receptor by both cell types with the greater contribution made by stromal cells.
TNF-α impacts the RANK/RANKL axis. Because the RANK/RANKL
axis is central to osteoclast recruitment, we asked if it is differentially impacted in the various chimeric mice (Figure 2A). Thus,
we administered TNF-α or carrier for 5 days and assayed BM for
both RANKL and its receptor. As we have shown, TNF-α induces
RANKL gene expression in WT to WT but not in KO to KO mice
(15). In keeping with their greater contribution to TNF-α–stimulated osteoclastogenesis, TNFRs on stromal cells, but not preosteoclasts, were necessary for RANKL induction by the cytokine. On the
other hand, RANK mRNA levels were equivalent whether osteoclast
precursors, stromal cells, or both express TNFRs. Thus, whereas
RANKL induction by TNF-α required direct targeting of stromal
cells, RANK mRNA expression by BMMs may have been stimulated
directly (WT to KO) or indirectly (KO to WT) by the cytokine.
M-CSF mediates TNF-induced osteoclastogenesis. To determine the
mechanism by which TNF-α simulates RANK via a stromal cell–
dependent mechanism, we turned to another stromal cell–produced osteoclastogenic cytokine, namely M-CSF, and asked if the
growth factor promotes RANK mRNA expression by BMMs. In
fact, like TNF-α, M-CSF induced RANK gene expression in a dosedependent fashion (Figure 2B). Therefore, the indirect stimulatory
effect of TNF-α on RANK mRNA expression may be mediated by
stromal cell induction of M-CSF.
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To further explore this issue, we asked if TNF-α induces
M-CSF expression in vivo in a stromal cell–dependent fashion. We
therefore injected TNF-α into the 4 chimeric species of mice for
5 days, after which we assessed BM M-CSF mRNA levels. TNF-α
induced M-CSF mRNA in WT to WT and KO to WT but not in
WT to KO or KO to KO mice (Figure 2C). Hence, the capacity of
TNF-α to stimulate M-CSF gene expression requires the presence
of cytokine-responsive stromal cells.
M-CSF promotes osteoclastogenesis by stimulating proliferation
and survival of osteoclast precursors (17). If M-CSF represents a
means by which TNF-α indirectly promotes osteoclast recruitment,
one would expect absence of TNFRs on stromal cells to dampen
osteoclast precursor number. In this regard, TNF-α administered to mice increased the percentage of BM cells expressing the
macrophage marker CD11b (Figure 3). Furthermore, TNF-α–
mediated enhancement of osteoclast precursor number required
the cytokine receptor only on stromal cells, a source of M-CSF.
TNF-α enhancement of osteoclast precursor number is not mediated by
IL-1. TNF-α–induced osteoclastogenesis reflects both IL-1–dependent and –independent mechanisms (18). The IL-1 mediated event,
while involving BMMs, also participates in the effect of TNF-α on
stromal cells and has the capacity to directly induce RANKL expression (18). This observation raises the possibility that TNF-α–stimulated M-CSF production, and thus enhancement of osteoclast precursor number, is mediated via IL-1. To address this issue, we used
a VCAM-1 affinity column to isolate BM stromal cells from WT
mice and those deleted of IL-1RI (18). The cells were then exposed
to TNF-α or IL-1–α. As seen in Figure 4, TNF-α, but not IL-1–α,
induced M-CSF gene expression in WT stromal cells, and the effect
was not impacted by IL-1 receptor antagonist (IL-1Ra). The fact
that IL-1 did not mediate TNF-α induction of M-CSF mRNA is

further confirmed by the lack of impact of IL-1RI deletion. Again
consistent with stimulated M-CSF synthesis, TNF-α enhancement
of osteoclast precursor number in vivo was unaltered in mice lacking IL-1–α or its receptor (Figure 5).
Stromal cells or BMMs mediate optimal inflammatory osteolysis.
We have shown that the presence of TNFRs solely on osteoclast
precursors is sufficient to optimize bone loss in inflammatory
arthritis (15). On the other hand, stromal cells are the source of
TNF-α–induced M-CSF, and we therefore asked if the same occurs
only if they express TNFRs. Thus, arthrogenic serum or PBS was
administered to the 4 species of chimeric mice (19, 20). By 7 days,
all developed cutaneous inflammation (Figure 6A). Paw swelling
was also present in each, which, while identical in the 3 species
of TNFR-bearing animals, was substantially less in KO to KO
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SFTFBSDIBSUJDMF
resorptive cells juxtaposed to virtually the entire inflamed bone
surface (Figure 9, C and D). On the other hand, antibody-treated
mice exhibited a total arrest of arthritis-induced osteoclastogenesis despite persistence of profound inflammation.
In keeping with the clinical implications of these observations,
the increase in bone resorptive activity induced by inflammatory
arthritis was completely prevented in antibody-treated animals
(Figure 9E). Despite a small but significant decrease in serum tartrate-resistant acid phosphatase 5b (TRACP 5b) levels in arthritic
mice receiving anti–c-Fms as compared with naive animals, the
antibody appeared to exert a substantially greater impact on
inflammation-induced than physiological osteoclastogenesis, as
TRAP-expressing cells within the tibial metaphysis appeared to be
'JHVSF
abundant in each circumstance (Figure 9F).
5/'αJOEVDFT.$4'N3/"FYQSFTTJPOCZ#.TUSPNBMDFMMTJOEFQFO
Although TNF-α is a dominant mediator, the osteoclastoEFOUPG*-#.TUSPNBMDFMMTXFSFJTPMBUFEPOB7$".BGGJOJUZDPMVNO genesis of inflammatory arthritis is the product of a number
GSPN85PS*-3*mmNJDF7$".mQPTJUJWFDFMMTXFSFUIFOFYQPTFEUP
of cytokines. Therefore, as a final exercise, we asked if arrest of
DBSSJFS DPOUSPM PS5/'α *-α BOE*-3BBMPOFPSJODPNCJOBUJPOGPS
IPVST.$4'N3/"JOFRVBMBNPVOUTPGUPUBM3/"XBTEFUFSNJOFE M-CSF signaling specifically affects TNF-α–stimulated bone
resorption. WT mice were administered supracalvarial TNF-α
CZ351$3("1%)N3/"TFSWFEBTMPBEJOHDPOUSPM
daily, with or without anti–c-Fms mAb. Once again, control animals received only PBS. By 5 days, TNF-α alone induced a marked
mice (Figure 6B). Whereas periarticular inflammation was exten- osteoclastogenic response, which was completely prevented by
sive in the WT to WT, WT to KO, and KO to WT serum-injected c-Fms mAb (Figure 10, A and B). Similar to animals with inflammice, it was sparse in those devoid of TNFRs (Figure 6C). Impor- matory arthritis, this arrest of TNF-α–induced osteoclastogenesis
tantly, inflammatory osteolysis, as manifested by the percentage was paralleled by blunting of in vivo bone resorption manifested
of bone surface juxtaposed to osteoclasts, was indistinguishable by TRACP 5b serum to a level even lower than that of controls
in arthritic mice whether TNFRs were present on stromal cells, (Figure 10C). Again reflecting the relative sensitivity of osteoclast
preosteoclasts, or both (Figure 6, D and E). In contrast, no sig- recruitment as compared with precursor number to anti–c-Fms,
nificant osteoclastogenesis obtained in serum-injected KO to KO the antibody only nominally affected the number of CD11B cells
mice or any species administered PBS. Finally, osteoclast precursor
number, represented by CD11B expression, was also enhanced to
similar degrees in the BM of the 3 TNFR-bearing chimeras (Figure
7). These observations are in keeping with the hypothesis that, in
the context of severe inflammation, TNF-α enhances osteoclast
precursor number by stimulating stromal cell production of
M-CSF (KO to WT) or acting in concert with constitutive levels of
the latter cytokine (WT to KO).
Blockade of M-CSF–induced signaling prevents inflammatory osteolysis.
The data presented thus far raise the possibility that M-CSF plays
a central role in states of TNF-α–induced osteolysis, including
inflammatory arthritis. To explore the clinical implications of this
issue, we turned to a mAb generated against the M-CSF receptor,
c-Fms (21). To determine its efficacy, we added increasing amounts
of the antibody to cultures of WT BMMs in the presence of M-CSF
alone or induced to undergo osteoclastogenesis by M-CSF and
RANKL. After 3 days, we determined the number of BMMs and
osteoclasts, respectively. Figure 8 shows that substantial osteoclast
arrest occurred relative to control (0 ng/ml) at a dose (10 ng/ml) of
the antibody at least 1 order of magnitude lower than that impacting macrophage number (100 ng/ml).
This observation prompted us to assess the effect of the anti–
c-Fms mAb in inflammatory arthritis. Thus, WT mice administered arthrogenic serum received daily injections of anti–c-Fms
mAb or PBS. Nonarthritic animals received only PBS. Seven days
later, cutaneous inflammation (Figure 9A) and paw thickness (Fig- 'JHVSF
5/'αmNFEJBUFEJODSFBTFJOPTUFPDMBTUQSFDVSTPSOVNCFSJOWJWPJT
ure 9B) of mice treated with the antibody or PBS were indistin*-JOEFQFOEFOU5IFQFSDFOUBHFPGPTUFPDMBTUQSFDVSTPSTJO#.
guishable. Histological examination of the ankles confirmed the SFDPWFSFEGSPN85 *-3*mm BOE*-αmmNJDFBGUFSEBJMZJOKFDUJPOT
abundance of inflammation in each and its absence in nonarthrit- PG5/'α μHEBZ PSWFIJDMFXBTEFUFSNJOFECZ'"$4VTJOH'*5$
ic animals (Figure 9C). As expected, those serum-treated animals DPOKVHBUFEBOUJ$%CN"C GJMMFEQSPGJMFT BOE'*5$DPOKVHBUFEJTP
receiving PBS underwent extensive osteoclastogenesis with bone UZQFN"C PQFOQSPGJMFT 
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in TNF-α–treated mice (70.7% ± 0.6% vs. 90.2% ± 2.0% of isolated
BM cells) (Figure 10D).
%JTDVTTJPO
Rheumatoid arthritis is a complicated condition, as a host of
cytokines produced by a variety of cells contributes to its pathogenesis. While RANKL and IL-1 are important participants in
development of focal bone erosions, which eventuate in joint collapse, TNF-α is the principal and rate-limiting
culprit, as its blockade dampens both the inflammatory and osteoclastogenic components of the
disease (13). On the other hand, blockade of
TNF-α alone is insufficient to optimize arrest of
inflammatory joint disease, as coordinate treatment with IL-1Ra is more effective (14). Added
to the potential complications attending TNF-α

inhibition, these observations underscore the importance of identifying new therapeutic candidates in this disease, a goal which
can be achieved only by gaining insight into the means by which
TNF-α impacts its target cells.
Inflammatory osteoclastogenesis represents a complex relationship between macrophages and mesenchymal stromal cells,
including those in BM and synovium. Each produce, and are targets of, inflammatory cytokines such as TNF-α, which enhances
osteoclastogenesis by impacting both families of cells (15, 18). The
cytokine stimulates stromal cells to synthesize RANKL and IL-1.
TNF-α also directly prompts macrophages to differentiate into
osteoclasts when exposed to constitutive levels of the key osteoclastogenic cytokine, i.e., RANKL (10). Thus, our first exercise
was to determine the relative contributions of stromal cells and
macrophages to TNF-α–induced osteoclastogenesis. Because this
undertaking required isolating the contribution of each in vivo,
we turned to mice chimeric for TNFRs in the BM and stromal
compartment and found that, while both were required for optimal TNF-α–induced osteoclastogenesis, stromal cells had the
greater impact. This pronounced contribution of stromal cells
to the osteoclastogenic process involved stimulated production
of RANKL. Alternatively, TNF-α–induced RANK mRNA levels in
osteoclast precursors were similar whether TNFRs were present
on macrophages, stromal cells, or both. Thus, enhanced RANK
expression does not account for the dominant role played by
stromal cells in TNF-α-stimulated osteoclast recruitment.
RANKL and IL-1 are produced by stromal cells under the
influence of TNF-α, but the importance of these cells as indi-
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rect mediators of inflammatory osteolysis prompted us to ask
if their participation in this disorder reflects additional osteoclastogenic cytokines, such as M-CSF, which may also represent
therapeutic targets. M-CSF mediates survival and proliferation
of macrophage precursors and their differentiation into mature
phagocytes (17). Given the ontogeny of the osteoclast, it is not
surprising that the cytokine also plays an important role in the
maturation and survival of this cell. M-CSF also impacts the
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mature osteoclast by promoting organization of its cytoskeleton (16). The op/op mouse in particular underscores
the central role the cytokine plays in the osteoclastogenic
process. This animal, which bears a point mutation in the
Csf1 gene coding for M-CSF, is born osteopetrotic due to
failure to generate osteoclasts and is rescued by the cytokine
(22). The transmembrane tyrosine kinase, c-Fms, is the sole
M-CSF receptor (23, 24), and deletion of its gene leads to the
same phenotype as the op/op mouse (25).
While M-CSF is constitutively produced by a range of
mesenchymal cells, its regulated secretion has pathological
consequences in the context of the osteoclast. Thus, absence
of estrogen, the cause of postmenopausal osteoporosis, is
due to enhanced bone resorption caused at least in part by
increased production of M-CSF by BM stromal cells (26).
Similarly, the enhanced osteoclastogenesis attending deletion of the β3 integrin gene is due to stimulated M-CSF
expression (16). As regards inflammatory osteolysis, the
cytokine is increased in the serum of patients with rheumatoid arthritis (27) and those with severe ankylosing spondylitis (28) as well as in synovial fluid around loose joint prostheses (29). Taken together, these observations suggest that
stromal cell–produced M-CSF may be an important mediator of TNF-stimulated osteoclastogenesis. In fact, we find
that TNF-α induced M-CSF gene expression in vivo and did
so only in the presence of stromal cell–residing TNFRs. The
capacity of TNF-α to increase osteoclast precursor numbers,
in vivo, is in keeping with the proproliferative and prosurvival properties of abundant M-CSF.
IL-1, whose expression by BMMs and stromal cells is also
enhanced by TNF-α, mediates approximately 50% of the
osteoclastogenic capacity of TNF-α (18). IL-1, however, does
not participate in TNF-induced M-CSF production. Specifically, arrest of IL-1 signaling by either IL-1Ra or deletion of
the functional IL-1 receptor has no effect on the capacity of TNF-α
to promote M-CSF production or to increase osteoclast precursor
number in vitro and in vivo. Thus, M-CSF appears to be a mediator
of that component of TNF-stimulated osteoclastogenesis occurring in an IL-1–independent manner.
The development of models of inflammatory arthritis in the context of TNFR chimeric mice enables us to attribute various components of the disease, including synovitis and periarticular osteolysis,
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to specific cell types. We previously noted that osteoclastogenesis
induced by relatively modest levels of TNF-α requires TNF-responsive stromal cells (15). On the other hand, an abundance of the
cytokine, as obtains in inflammatory osteolysis, is capable of inducing maximal osteoclastogenesis by directly targeting only osteoclast
precursors in the presence of constitutive levels of RANKL (10, 15).
In this study, we show that the reciprocal is also true. Thus, mice
bearing TNFRs on stromal cells, but not osteoclast precursors, optimize inflammation-induced osteoclast recruitment. These observations indicate that in situations of abundant TNF expression, such
as rheumatoid arthritis, the cytokine’s effect is maximized by targeting either the osteoclast precursor or the stromal compartment.
The fact that TNF-α enhances osteoclast precursor number in the
presence of only constitutive levels of M-CSF suggests that, like its
interaction with RANKL, the inflammatory cytokine synergizes
with M-CSF to enhance osteoclast precursor number.
The Journal of Clinical Investigation

These data, taken in concert, indicate that M-CSF is yet another
cytokine playing a central role in inflammatory osteolysis and
might be a therapeutic target. M-CSF, however, accelerates formation of osteoclasts by increasing their precursor pool, the majority
of which does not become bone resorptive polykaryons, but host
defense mononuclear phagocytes. Thus, the coincident immunosuppressive effect of inhibiting macrophage proliferation and survival as a means of arresting inflammatory periarticular erosion
is a potential limitation of M-CSF blockade. On the other hand,
anti–c-Fms mAb prevents RANKL and M-CSF–induced osteoclast
formation at a concentration at least 1 order of magnitude less
than its capacity to decrease cell number in vitro. This observation raises the possibility that, in the context of inflammatory
osteolysis, osteoclast recruitment is more sensitive to M-CSF inhibition than is macrophage proliferation and/or survival. In fact,
mice treated with carrier or anti–c-Fms mAb developed equivalent periarticular inflammation while those receiving the antibody were completely free of pathological osteoclastogenesis and
bone resorption. This observation reflects to a substantial degree
arrest of TNF signaling, as similar results obtained in TNF-α–
injected mice also receiving anti–c-Fms mAb. Like arthritic animals, those directly receiving TNF-α experienced complete arrest
of osteoclastogenesis but only a modest decrease in macrophage
number. Interestingly, nonpathological osteoclastogenesis located
distant from the inflamed joint was robust in each case. While the
enhanced sensitivity to c-Fms arrest of pathological, as compared
with physiological, osteoclastogenesis remains unexplained, it
may reflect participation of redundant cytokines. For example, the
osteopetrosis and arrested osteoclastogenesis of the M-CSF–deficient op/op mouse resolves with age due to expression of VEGF
(30), GM-CSF, and/or IL-3 (31). While speculative, the possibility
remains that these 2 cytokines substitute for M-CSF in a physiological setting of osteoclast recruitment.
Thus, M-CSF joins the panoply of cytokines involved in the
pathogenesis of inflammatory osteolysis. Although this study represents short-term arrest of M-CSF signaling initiated at induction
of the arthritic process, the profundity of its effect on osteoclasts
as compared with macrophages enhances its therapeutic appeal.
The potential of M-CSF inhibition as a means of treating rheumatoid arthritis is underscored by the development of c-Fms–selective small molecules (32) and the capacity of the tyrosine kinase
inhibitor drug Imatinib to target the receptor (33). Given the significant complications encountered with other forms of anticytokine therapy, however, the therapeutic targeting of M-CSF must be
approached with caution (34).
.FUIPET
Mice. C57BL/6 mice deleted of genes coding for both TNFR type 1 and
TNFR type 2 on a C57BL/6 background were generated as described (15).
C57BL/6 WT mice were purchased from the Jackson Laboratory. Animals
were housed in the animal care unit of the Department of Pathology,
Washington University School of Medicine, and were maintained according to the guidelines of the Association for Assessment of Laboratory Animal Care. All animal experimentation was approved by the Animal Studies
Committee of Washington University School of Medicine.
Reagents. The following mAbs were obtained from BD Biosciences: purified
rat anti-mouse VCAM-1 (no. 553330), purified rat anti-mouse CD3 molecular complex (no. 555273), FITC-conjugated rat anti-mouse CD11b (no.
553310), purified hamster anti-mouse TNFR1 (no. 559915), PE-conjugated
hamster anti-mouse TNFR2 (no. 550086), and isotype control antibodies.
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Goat anti-rat IgG microbeads for immunopurification were obtained from
Miltenyi Biotec. Recombinant murine TNF-α was prepared in our laboratory as described (15). Recombinant human M-CSF was generously provided
by Daved H. Fremont (Washington University, St. Louis, Missouri, USA).
Murine RANKL was expressed in our laboratory as described (10).
BM transplantation. Mice were killed by CO2 gas, and femoral BM cells
were flushed with culture medium as described (35). VCAM-1 and CD3positive cells were depleted from BM by negative selection using MACS
goat anti-rat IgG Microbeads (Miltenyi Biotec) as described (15). One day
after administration of 10 Gy of total body γ-irradiation, we injected 1 × 106
CD3 and VCAM-1 depleted BM cells in 100 μl PBS into 4- to 6-week-old
male mice via tail vein.
In vivo T cell depletion. Female ICR-SCID mice (Taconic) were primed by
intraperitoneal injection of 0.5 ml of incomplete Freund’s adjuvant. After
7 days, the mice received intraperitoneal injections of 5 × 106 YTS cells,
which secrete anti-CD4 antibodies, or H35 cells, which secrete anti-CD8
antibodies (kindly provided by Osami Kanagawa, Washington University,
St. Louis, Missouri, USA). One to 2 weeks later, ascites was recovered, incubated at 37°C for 1 hour, and transferred to 4°C overnight. Cells and oil
were removed by centrifugation, and ascites was stored at –80°C. Mice were
administered 4 weekly injections of 50 μl of anti-CD4 and anti-CD8 ascites
to assure arrest of T cell generation in vivo (15).
FACS analysis. To assess the number of osteoclast precursors, freshly isolated
BM cells were incubated in NaN3 (0.1%) plus FBS-PBS (FBS, 1%) for 30 minutes with FITC-conjugated rat anti-mouse CD11b mAb. The samples were
diluted with the same solution and analyzed by FACS for CD11b-expressing cells. To evaluate BM engraftment, BMMs were incubated for 30 minutes
with anti-TNFR1 mAb and then for 30 minutes with FITC-conjugated antiIgG mAb. They were then washed and diluted with NaN3 plus FBS. A second
aliquot of BM cells was incubated for 30 minutes with PE-labeled anti-TNFR2
mAb. TNFR1 and TNFR2 expression were analyzed by FACS.
RNA preparation and RT-PCR analysis. Total RNA from BM cells was isolated by RNeasy mini kit (QIAGEN). For RT-PCR analysis, cDNA was synthesized from 1 μg of total RNA using reverse transcriptase and oligo-dT
primers in a volume of 20 μl. PCR was performed with a cDNA reaction
mixture using PCR supermix (Invitrogen Corp.) and appropriate primers in
a volume of 50 μl. The following primers were used: GAPDH, 5′-ACTTTGTCAAGCTCATTTCC-3′ and 5′-TGCAGCGAACTTTATTGATG-3′; RANK,
mouse RANK PCR Primer Pair (R&D Systems); RANKL, human/mouse
TRANCE/TNFSF11 PCR Primer Pair (R&D Systems.); and M-CSF, 5′GACTTCATGCCAGATTGCC-3′ and 5′-GGTGGCTTTAGGGTACAGG-3′.
Samples were transferred to a programmable thermal cycler (Hybaid; Thermo Electron Corporation) preheated to 94°C. Each cycle consisted of a
denaturation step at 94°C for 45 seconds, an annealing step at 55°C for 45
seconds, and an extension step at 72°C for 45 seconds for RANKL, RANK,
and GAPDH and a denaturation step at 94°C for 1 minute, an annealing
step at 58°C for 1 minute, and an extension step at 72°C for 1 minute for
M-CSF. We separated 10-μl aliquots of PCR products by electrophoresis
on a 2.0% agarose gel.
Serum transfer arthritis. KRN-TCR transgenic mice on a C57BL/6 background were kindly provided by D. Mathis and C. Benoist (Harvard Uni1. Udagawa, N., et al. 1990. Origin of osteoclasts:
mature monocytes and macrophages are capable
of differentiating into osteoclasts under a suitable
microenvironment prepared by bone marrowderived stromal cells. Proc. Natl. Acad. Sci. U. S. A.
87:7260–7264.
2. Lacey, D.L., et al. 1998. Osteoprotegerin ligand is
a cytokine that regulates osteoclast differentiation
and activation. Cell. 93:165–176.
3. Yasuda, H., et al. 1998. Osteoclast differentiation fac

versity Medical School, Boston, Massachusetts, USA). K/BxN mice, which
spontaneously develop severe inflammatory arthritis (18) and whose serum
immunoglobulin is arthrogenic in a T cell–independent manner (15), in
mouse strains other than KRN, were generated by breeding KRN-TCR with
nonobese diabetic mice (Taconic). Serum was obtained from 6- to 12-weekold K/BxN mice, pooled, and stored in aliquots at –70°C. T cell–depleted
WT to WT, WT to KO, KO to WT, and KO to KO mice were injected once
intraperitoneally with 200 μl of serum or PBS. Paw thickness was measured
with a caliper daily for 10 days. A second group of animals was sacrificed
at day 7 for histology and FACS analysis. Paws were stripped of soft tissue,
and bones and joints were subjected to histological examination and evaluation of numbers of CD11b-positive cells.
Administration of anti–c-Fms antibody. AFS98, a rat monoclonal, antimurine c-Fms antibody (IgG2a) that inhibits M-CSF–dependent colony
formation and cell growth by blocking the binding of M-CSF to its receptor, has been described (21). The AFS98 hybridoma was kindly supplied
by Shin-Ichi Nishikawa (Graduate School of Medicine, Kyoto University
Medical School, Kyoto, Japan). The clone was maintained in HyQ-CCM1
medium (HyClone), and the antibody was purified using Protein G (SigmaAldrich). We administered intraperitoneally 500 μm of AFS98 in 500 μl of
PBS or PBS alone every day for 7 days to arthritic or TNF-injected mice.
Macrophage proliferation assay. BMMs from WT mice were cultured with
several doses of AFS98 mAb in the presence of 100 ng/ml M-CSF. After
3 days, the number of viable cells was measured using the MTT (3-[4,5dimethylthiazol-2yl]-2,5-diphenyltetrazoliun bromide; Sigma-Aldrich)
assay. In brief, 10 μl MTT (5 mg/ml) was added to 100 μl culture medium
in each well and incubated at 37°C for 4 hours. We added 150 μl 0.04N
HCl in isopropanol to each well to stop the reaction, and MTT absorbance
was determined at OD of 570 nm.
Serum TRACP 5b assay. Serum was obtained 7 days after injection of
arthrogenic serum or following 5 days of daily TNF-α administration.
TRACP 5b levels were determined according to the protocol of the
MouseTRAP Assay kit (IDS).
Histological analysis. Osteoclast number was determined using the Osteomeasure System version 2.2 (Osteometrics Corp.).
Statistics. All data are expressed as mean ± SD. Statistical significance was
calculated by 2-tailed Student’s t test.
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